Omega-3 fatty acid ester compositions
View Patent ↗Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. The compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions on how to administer the compositions.
1. A pharmaceutical composition which self-micellizes upon contact with an aqueous medium to form spherical micelles which have an average diameter of from about 1 μm to about 10 μm, and provide for absorption of omega-3 fatty acid esters substantially free of any food effect comprising:
a mixture of (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid (EPA) ethyl ester and (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid (DHA) ethyl ester and at least one surface active agent;
wherein the ratio of said EPA:DHA ethyl esters is from more than 2:1 to not more than 3.4:1 and wherein said EPA and DHA ethyl esters combined comprise from about 60% (wt/wt) to about 70% (wt/wt) of said composition;
wherein said at least one surface active agent comprises, in combination, at least one non-ionic polyoxyethylene glycol sorbitan alkyl ester (a polysorbate) selected from the group consisting of polyoxyethylene (20) sorbitan monolaurate (polysorbate 20), polyoxyethylene (20) sorbitan monopalmitate (polysorbate 40), polyoxyethylene (20) sorbitan monostearate (polysorbate 60) and polyoxyethylene (20) sorbitan monooleate (polysorbate 80); and
a block copolymer of polyethylene glycol and polypropylene glycol having the formula [(HO(C 2 H 4 O) 64 (C 3 H 6 O) 37 (C 2 H 4 O) 64 H] (Poloxamer 237);
wherein said at least one polysorbate is present in an amount within the range of about 15% (wt/wt) to about 31% (wt/wt); and
said Poloxamer 237 is present in an amount within the range of about 0.5% (wt/wt) to about 5% (wt/wt);
wherein said composition is free of active ingredients other than omega-3 fatty acid esters; and wherein said composition when administered to a human at equal dosage strengths provides for substantially the same bioavailability when administered with or without food to said human in need of such administration; and
whereby said pharmaceutical composition self-micellizes in an aqueous medium, thus forming spherical micelles having an average diameter of from about 1 μm to about 10 μm, which provide for absorption of said omega-3 fatty acid esters substantially free of any food effect.
2. The pharmaceutical composition of claim 1 , wherein said ratio of said EPA:DHA ethyl esters is about 2.4:1.
3. The pharmaceutical composition according to claim 1 , further comprising d-limonene.
4. The pharmaceutical composition of claim 1 , wherein said composition is free of omega-3 free fatty acids.
5. The pharmaceutical composition according to claim 1 , wherein said polysorbate is present in an amount within the range of about 20% (wt/wt) to about 31% (wt/wt).
6. The pharmaceutical composition according to claim 5 , wherein said polysorbate is polysorbate 80.
7. The pharmaceutical composition according to claim 1 , wherein said composition further comprises from about 0.01% to about 5% by weight of the composition, of at least one antioxidant selected from the group consisting of a tocopherol, a tocotrienol, and combinations thereof.
8. A micelle dosage form pharmaceutical composition comprising pre-formed micelles in an aqueous medium, wherein said dosage form pharmaceutical composition is prepared by adding the pharmaceutical composition of claim 1 to an aqueous medium.